|
1
|
Nonsteroidal anti-inflammatory drugs repress beta-secretase gene promoter activity by the activation of PPARgamma.
|
Proc Natl Acad Sci U S A
|
2006
|
1.81
|
|
2
|
Amyloid activates GSK-3beta to aggravate neuronal tauopathy in bigenic mice.
|
Am J Pathol
|
2008
|
1.65
|
|
3
|
Improved long-term potentiation and memory in young tau-P301L transgenic mice before onset of hyperphosphorylation and tauopathy.
|
J Neurosci
|
2006
|
1.41
|
|
4
|
Changed conformation of mutant Tau-P301L underlies the moribund tauopathy, absent in progressive, nonlethal axonopathy of Tau-4R/2N transgenic mice.
|
J Biol Chem
|
2004
|
1.40
|
|
5
|
AAV-tau mediates pyramidal neurodegeneration by cell-cycle re-entry without neurofibrillary tangle formation in wild-type mice.
|
PLoS One
|
2009
|
1.23
|
|
6
|
Mice lacking phosphatase PP2A subunit PR61/B'delta (Ppp2r5d) develop spatially restricted tauopathy by deregulation of CDK5 and GSK3beta.
|
Proc Natl Acad Sci U S A
|
2011
|
1.09
|
|
7
|
Upper airway dysfunction of Tau-P301L mice correlates with tauopathy in midbrain and ponto-medullary brainstem nuclei.
|
J Neurosci
|
2010
|
1.08
|
|
8
|
GSK-3α/β kinases and amyloid production in vivo.
|
Nature
|
2011
|
1.05
|
|
9
|
Dendritic degeneration, neurovascular defects, and inflammation precede neuronal loss in a mouse model for tau-mediated neurodegeneration.
|
Am J Pathol
|
2011
|
1.04
|
|
10
|
Alzheimer's disease: old problem, new views from transgenic and viral models.
|
Biochim Biophys Acta
|
2010
|
1.02
|
|
11
|
Efficacy and safety of a liposome-based vaccine against protein Tau, assessed in tau.P301L mice that model tauopathy.
|
PLoS One
|
2013
|
1.00
|
|
12
|
Identification and isolation of a hyperphosphorylated, conformationally changed intermediate of human protein tau expressed in yeast.
|
Biochemistry
|
2005
|
0.95
|
|
13
|
Early improved and late defective cognition is reflected by dendritic spines in Tau.P301L mice.
|
J Neurosci
|
2011
|
0.95
|
|
14
|
Neurodegeneration and neuroinflammation in cdk5/p25-inducible mice: a model for hippocampal sclerosis and neocortical degeneration.
|
Am J Pathol
|
2008
|
0.95
|
|
15
|
Neuronal or glial expression of human apolipoprotein e4 affects parenchymal and vascular amyloid pathology differentially in different brain regions of double- and triple-transgenic mice.
|
Am J Pathol
|
2006
|
0.94
|
|
16
|
Transgenic mouse models for APP processing and Alzheimer's disease: early and late defects.
|
Subcell Biochem
|
2005
|
0.93
|
|
17
|
beta-site amyloid precursor protein cleaving enzyme 1 increases amyloid deposition in brain parenchyma but reduces cerebrovascular amyloid angiopathy in aging BACE x APP[V717I] double-transgenic mice.
|
Am J Pathol
|
2004
|
0.92
|
|
18
|
Astrocytic calcium/zinc binding protein S100A6 over expression in Alzheimer's disease and in PS1/APP transgenic mice models.
|
Biochim Biophys Acta
|
2004
|
0.92
|
|
19
|
Raphé tauopathy alters serotonin metabolism and breathing activity in terminal Tau.P301L mice: possible implications for tauopathies and Alzheimer's disease.
|
Respir Physiol Neurobiol
|
2011
|
0.88
|
|
20
|
Age-related impairment of ultrasonic vocalization in Tau.P301L mice: possible implication for progressive language disorders.
|
PLoS One
|
2011
|
0.84
|
|
21
|
Isoflurane anesthesia precipitates tauopathy and upper airways dysfunction in pre-symptomatic Tau.P301L mice: possible implication for neurodegenerative diseases.
|
Neurobiol Dis
|
2012
|
0.83
|
|
22
|
Neurological characterization of mice deficient in GSK3α highlight pleiotropic physiological functions in cognition and pathological activity as Tau kinase.
|
Mol Brain
|
2013
|
0.82
|
|
23
|
Terminal hypothermic Tau.P301L mice have increased Tau phosphorylation independently of glycogen synthase kinase 3α/β.
|
Eur J Neurosci
|
2014
|
0.77
|
|
24
|
Tauopathy differentially affects cell adhesion molecules in mouse brain: early down-regulation of nectin-3 in stratum lacunosum moleculare.
|
PLoS One
|
2013
|
0.77
|
|
25
|
Virosome-based active immunization targets soluble amyloid species rather than plaques in a transgenic mouse model of Alzheimer's disease.
|
J Mol Neurosci
|
2005
|
0.77
|